MUNICH, Germany, Feb. 21 (UPI) -- GPC Biotech said Wednesday a new U.S. program would provide its prostate-cancer treatment satraplatin to patients free of charge.
The program, known as the Satraplatin Expanded Rapid Access, or SPERA, is intended to provide the investigational drug to patients who have no other treatment options.
"There is an important medical need for treatments for hormone-refractory prostate cancer patients whose first-line chemotherapy has failed," said Dr. Martine George, GPC Biotech's senior vice president of clinical development.
"We look forward to working with clinicians to make satraplatin available through the SPERA program to these patients who currently have no approved treatment options for their disease," George added.
GPC Biotech has submitted its new drug application for satraplatin to the U.S. Food and Drug Administration, which has granted fast-track status to the drug.
